NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial

Part of paid clinical trials in San Francisco, California.

Sponsor
Kaiser Permanente
Study ID
NCT04750616
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Acute Kidney Injury
  • Ischemia Reperfusion Injury
  • Myocardial Injury

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Niacinamide — DRUG
    Niacinamide 3 grams on the day of surgery and post-surgical days one and two
  • Placebo — DRUG
    Matched placebo on the day of surgery and post-surgical days one and two

Study Details

A Randomized, Double-blind, placebo-controlled Trial to Evaluate the Efficacy of Oral Nam for the Prevention of Acute Kidney Injury in Patients Undergoing On-Pump Cardiac Surgery

Key Dates

Start date
Sep 13, 2021
Status verified
Mar 2025
Primary completion
Apr 30, 2025
Completion
Jun 30, 2025

Study Design

Enrollment
304 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: Oral niacinamide
  • Placebo Comparator: Matched placebo

Primary Outcome Measure

Troponin T AUC [ Time Frame: From baseline to three days after surgery ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Kaiser Permanente San Francisco Medical CenterSan FranciscoCalifornia94115
Ali Poyan Mehr, MD
Ahmad Sheikh, MD (SUB_INVESTIGATOR)
Andrew Avins, MD (SUB_INVESTIGATOR)
Lance Rtherford, MD (SUB_INVESTIGATOR)
Paul LaPunzina, MD (SUB_INVESTIGATOR)

Find similar trials in San Francisco, CA

By research site
Kaiser Permanente San Francisco Medical Center· San Francisco, CA

Related Studies